Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer
Darryl P. Leong, Celestia Higano, Cristina Cano Garcia, Vincent Fradet et autres
0 citationsJAMA Internal Medicine
Ariel Galapo Kann
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
32Publications signalées
1328Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Bladder and Urothelial Cancer TreatmentsProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersCancer, Lipids, and Metabolism
Publications récentes
Microbiota intestinal: o exército invisível no tratamento do câncer
0 citations
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
Thomas Powles, Ariel Galapo Kann, Daniel Castellano, Marine Gross‐Goupil et autres
135 citationsNew England Journal of Medicine
PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum
Joshua J. Meeks, Michiel S. van der Heijden, Thomas Powles, Matthew D. Galsky et autres
0 citationsThe Journal of Urology
2472P Initial management of newly diagnosed non-metastatic prostate cancer according to age-group: A RADICAL-PC substudy
C. Cano Garcia, Jehonathan H. Pinthus, Steven Agapay, Kelvin Kuan Huei Ng et autres
0 citationsAnnals of Oncology
WITHDRAWN: 2427P Association between metformin use in individuals with prostate cancer and mortality: An analysis of the RADICAL-PC study
Jehonathan H. Pinthus, Muatasim Noorelahi, J. Moryosef, Daniel Taussky et autres
0 citationsAnnals of Oncology
LBA8 IMvigor011: A phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer
Tom Powles, Ariel Galapo Kann, D.E. Castellano Gauna, M. Gross Goupil et autres
3 citationsAnnals of Oncology
PD37-09 THE FIRST REPORT OF DISEASE-FREE SURVIVAL ANALYSES FROM THE NIAGARA TRIAL OF PERIOPERATIVE DURVALUMAB PLUS NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER
Joshua J. Meeks, Michiel S. van der Heijden, Thomas Powles, Matthew D. Galsky et autres
0 citationsThe Journal of Urology
GC2 – Surgical outcomes and neoadjuvant safety with perioperative durvalumab for muscle-invasive bladder cancer (NIAGARA)
James W.F. Catto, Hikmat Al‐Ahmadie, Michiel S. van der Heijden, T. Powles et autres
0 citationsEuropean Urology
DISEASE-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE BLADDER CANCER WHO HAVE PERSISTENT CIRCULATING TUMOR DNA-NEGATIVE BIOMARKER STATUS POST-CYSTECTOMY: IMVIGOR011 STUDY SURVEILLANCE ANALYSIS
Joaquim Bellmunt, Jürgen E. Gschwend, J. B. Jensen, Marine Gross‐Goupil et autres
2 citationsUrologic Oncology Seminars and Original Investigations
Frailty and adverse clinical outcomes in prostate cancer patients: An analysis from the RADICAL-PC cohort.
Rocío Consuelo Baro Vila, Jehonathan H. Pinthus, Sarah Karampatos, Cristina Cano Garcia et autres
0 citationsJournal of Clinical Oncology
Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.
Matthew D. Galsky, Michiel Simon Van Der Heijden, James W.F. Catto, Hikmat Al‐Ahmadie et autres
9 citationsJournal of Clinical Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.